H840 Oxonic acid potassium salt - AK Scientific
 
 
Loading Please Wait...
  Catalog ID # H840
Oxonic acid potassium salt
, 98% (HPLC)
 
4,6-Dihydroxy-1,3,5-triazine-2-carboxylic acid potassium salt
Allantoxanic acid
Potassium oxonate




IDENTITY
CAS Registry #:[2207-75-2]
MDL Number:MFCD00010565
MF:C4H2KN3O4
MW:195.1747
EINECS:218-627-5
BRN:4049961
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Available Spectra:LCMS, HPLC
Physical Form:White to off-white powder
Melting Point:>300°C
Shipping:Normal Temperature

REVIEW

 Oxonic acid potassium salt is a biochemical modulator in the tegafur/gimeracil/oxonic acid potassium salt combination anticancer drug, which is used for the treatment of advanced gastric cancer and hepatocellular carcinoma. Due to its low permeability, oxonic acid potassium salt stays in the gut, where it reduces the production of 5-fluorouracil by blocking the enzyme orotate phosphoribosyltransferase. Lower 5-fluorouracil levels in the gut result in a lower gastrointestinal toxicity. A similar approach is present in S-1-gimeracil and oteracil potassium used for the treatment of gastric cancer.

REFERENCES
[1]Piskala, A.; Gut, J. Nucleic acid components and their analogs. XX. Synthesis of oxonic acid (2,4-dioxo-1,2,3,4-tetrahydro-1,3,5-triazine-6-carboxylic acid) and the acetylation of 2,4-dioxohexahydro-1,3,5-triazines Collection of Czechoslovak Chemical Communications (1962), 27, 1562-71.
[2] Piskala, Alois; Gut, Jiri Potassium 1,2,3,4-tetrahydro-2,4-dioxo-s-triazine-6-carboxylate (potassium 5-aza-orotate). Cyclocondensation of biuret with ethyl potassium oxalate Edited by Townsend, Leroy B.; Tipson, R. Stuart , Nucleic Acid Chem. (1978), 1, 93-5.
[3] Sugi, Mitsuyo; Igi, Masami Preparation of potassium oxonate by oxidation of allantoin using alkali metal hypohalite. Eur. Pat. Appl. (1999), EP 957096 A1 19991117.
[4] Kobayakawa M, Kojima Y.Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther. 2011;4:193-201.

Risk Description(s)
R36/37/38:Irritating to eyes, respiratory system and skin

Safety Description(s)
S24/25:Avoid contact with skin and eyes.


Pricing (not showing? please refresh your web browser)

CATEGORIES

 APIs and Bioactives > Chemotherapeutics

USEFUL LINKS

  PubChem